Abstract
The current study investigated the impact of different doses of
seeds on the symptoms, the cluster of differentiation profile group, and inflammatory markers of mild COVID-19 cases.
The study was a double-blind placebo-controlled clinical trial. Patients with mild and asymptomatic SARS-CoV-2 infection patients were randomly subdivided into seven subgroups: Group (GP) 1: received charcoal capsules as a control group, and GP 2: received three capsules of whole
seeds daily, two capsules in the morning and one in the evening; GP 3: received three capsules of whole
seeds every 12 h, GP 4: received five capsules in the morning and four capsules of whole
seeds in the evening, GP 5: received one capsule of
powder every 12 h; GP 6: received two capsules of
powder every 12 h; GP 7: received three capsules of
powder every 12 h; all treatment course was for ten days. Inflammatory parameters were assessed before and after interventions.
262 subjects were included in the final analysis. No significant difference was detected regarding age, gender, and nationality. No significant differences were detected between the inflammatory marker in all groups. The WBCs showed a significant difference between before and after the intervention. While for procalcitonin, a significant difference was demonstrated in groups 1,4, and 6.
The current randomized clinical trial did not reveal a significant effect of ten days of treatment with various doses of
on symptoms, differentiation profile, and inflammatory markers of patients with COVID-19. As a natural product, the effect of
on disease requires weeks to manifest itself.